Search

Your search keyword '"Fietz T"' showing total 173 results
Start Over Author "Fietz T"
173 results on '"Fietz T"'

2. Versorgungsrealität in Deutschland und Österreich – Zweite Interimsanalyse der nicht-Interventionellen Studie PERFORM für PatientInnen mit HR+/HER2- fortgeschrittenem Brustkrebs, die in der Erstlinie mit endokrin-basierter Palbociclib-Therapie behandelt werden

Author

Singer, C F, additional, Radosa, J, additional, Fietz, T, additional, Wilke, J, additional, Frank, M, additional, Gratzke, K, additional, Adams, A, additional, Buder, A, additional, Seidel, S, additional, Lux, M P, additional, and Bartsch, R, additional

Published
2023
Full Text
View/download PDF

4. Simultaneous Double-Purging of Breast Cancer Cells from Leukapheresis Products by Immunomagnetic CD34+ Cell Enrichment and Tumor Cell Depletion

Author

Mohr, M., Hilgenfeld, E., Fietz, T., Hoppe, B., Koenigsmann, M., Hoffmann, M., Knauf, W. U., Cassens, U., Sibrowski, W., Thiel, E., Kienast, J., Berdel, W. E., Berdel, W. E., editor, Büchner, Th., editor, Kienast, J., editor, Van De Loo, J., editor, Jürgens, H., editor, Ritter, J., editor, and Vormoor, J., editor

Published
2000
Full Text
View/download PDF

5. First interim results of the PERFORM study evaluating palbociclib in combination with endocrine therapy for HR+/HER2- advanced breast cancer

Author

Lux, M.P., additional, Wilke, J., additional, Deryal, M., additional, Fietz, T., additional, Schöttker, B., additional, Jacobasch, L., additional, Petersen, V., additional, Weigel, M., additional, Wrobel, D., additional, Glastetter, E., additional, Berger, L., additional, Frank, M., additional, Woerner, S.M., additional, Adams, A., additional, and Wöckel, A., additional

Published
2022
Full Text
View/download PDF

6. 49P EGFR exon 20 insertion mutations in patients with locally advanced or metastatic NSCLC in the German prospective, CRISP Registry real-world cohort (AIO-TRK-0315)

Author

Griesinger, F., primary, Sebastian, M., additional, Bethge, A., additional, Christopoulos, P., additional, Hoffknecht, P., additional, Waller, C., additional, Benkelmann, R., additional, Jänicke, M., additional, Fleitz, A., additional, Hanselmann, J., additional, Hipper, A., additional, Groth, A., additional, Weichert, W., additional, Nusch, A., additional, Rauh, J., additional, Fietz, T., additional, Illmer, T., additional, Depenbusch, R., additional, Eberhardt, W.E.E., additional, and Thomas, M., additional

Published
2022
Full Text
View/download PDF

9. 1871TiP PLATON – “Platform for Analyzing Targetable Tumor Mutations”: A pilot study

Author

Vogel, A., primary, Behringer, D.M., additional, Bröckling, S., additional, Chater, J., additional, Derigs, H-G., additional, Fietz, T., additional, Götze, T.O., additional, Hartmann, F., additional, Lutz, M.P., additional, Müller, L., additional, Moosmann, N., additional, Moulin, J-C., additional, Potenberg, J., additional, Saborowski, A., additional, Späth-Schwalbe, E., additional, Schuler, M.K., additional, Pauligk, C., additional, Westphalen, C.B., additional, Zäpf, B., additional, and Al-Batran, S-E., additional

Published
2021
Full Text
View/download PDF

12. Patient-reported outcomes (PROs) including treatment expectation and satisfaction in HR+/HER2- Advanced Breast Cancer patients treated: Real-world Results of the PERFORM study from interim analysis 3 (IA3).

Author

Bjelic-Radisic, V., Korell, M., Pfeiler, G., Radosa, J., Decker, T., Deryal, M., Fietz, T., Köhler, A., Schöttker, B., Wilke, J., Knoblich, J., Petersen, V., Dietrich, M., Gabrysiak, T., Kontou, M., Glasstetter, M., Oppermann, U., Glastetter, E., Adams, A., and Bartsch, R.

Published
2024
Full Text
View/download PDF

18. 1884P Patient, nurse and physician preferences: Final results of the CONVENIENCE study evaluating pegfilgrastim prophylaxis via pre-filled syringe or On-body injector (OBI) in cancer patients

Author

Metz, M., primary, Semsek, D., additional, Rogmans, G., additional, Hutzschenreuter, U., additional, Fietz, T., additional, Harde, J., additional, Zacharias, S., additional, Hielscher, C., additional, Lorenz, A., additional, Zahn, M-O., additional, Guth, D., additional, Grebhardt, S., additional, Fichter, C.D., additional, and Potthoff, K., additional

Published
2020
Full Text
View/download PDF

22. 14. Clinical Results in Lymphoma I: 060 RITUXIMAB PLUS MITOXANTRONE, CHLORAMBUCIL, PREDNISOLON (R-MCP) IS SUPERIOR TO MCP ALONE IN ADVANCED INDOLENT AND FOLLICULAR LYMPHOMA RESULTS OF A PHASE III STUDY (OSHO39)

Author

Herold, M., Pasold, R., Srock, S., Neser, S., Niederwieser, D., Neubauer, A., Dölken, G., Naumann, R., Fietz, T., Knauf, W., Freund, M., Rohrberg, R., Höffken, K., Franke, A., Ittel, T. H., Kettner, E., Haak, U., Mey, U., Klinkenstein, C., Assmann, M., Grünhagen, U. V., Dachselt, K., Schwenke, H., Bleyl, D., Wolf, H., Hahnfeld, S., Hoffmann, F. A., Lakner, V., Richter, P., Hahling, D., Wolf, H. H., Eschenburg, H., Clemens, M. R., Grobe, N., and Behringer, D.

Published
2005

26. West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast Cancer

Author

Nitz, Ulrike, Gluz, Oleg, Clemens, Michael, Malter, Wolfram, Reimer, Toralf, Nuding, Benno, Aktas, Bahriye, Stefek, Andrea, Pollmanns, Anke, Lorenz-Salehi, Fatemeh, Uleer, Christoph, Krabisch, Petra, Kuemmel, Sherko, Liedtke, Cornelia, Shak, Steven, Wuerstlein, Rachel, Christgen, Matthias, Kates, Ronald E., Kreipe, Hans H., Harbeck, Nadia, Ackermann, S., Aktas, B., Augustin, D., Baake, G., Baumann, K., Berger, R., Bettscheider, J., Bischoff, J., Clemens, M., Deryal, M., Dubbers, H., Duchting, D., Dunnebacke, J., Fett, W., Fietz, T., Fischer, H., Forner, M., Forstbauer, H., Freese, K., Geberth, M., Glados, M., Gnauert, K., Goette, O., Gohring, U., Goppinger, A., Grafe, A., Hackenberg, R., Hackmann, J., Hellriegel, M., Heyl, V., Hoestermann, C., Hoffmann, G., Hofmann, M., Hucke, J., Jackisch, C., Jungberg, P., Just, M., Kahl, C., Klare, P., Kogel, M., Kohls, A., Amrawy, B. Konigs-El, Konnecke, P., Krabisch, P., Kraudelt, S., Kremers, S., Kummel, S., Kurbacher, C., Kusche, J., Liedtke, B., Liedtke, C., Link, H., Lorenz, R., Salehi, F. Lorenz, Lubbe, K., Malter, W., Melekian, B., Mobus, V., Montenarh, M., Mueller, V., Mundhenke, C., Niederle, N., Nitz, U., Noesselt, T., Oberhoff, C., Paas, L., Paepke, S., Pollmanns, A., Reichert, D., Reimer, T., Romann, D., Ruhland, T., Runde, V., Salem, M., Schlosser, A., Schneider, A., Schrader, I., Schulz, H., Schumacher, C., Schwickerath, J., Soling, U., Stauder, H., Stefek, A., Steinmetz, T., Stickeler, E., Terhaag, J., Thomssen, C., Tome, O., Uleer, C., Warm, M., Wachsmann, G., Wacker, J., Wiebringhaus, H., Wiest, W., Wolfgarten, M., Christgen, H., Kreipe, H., Buehne, C., Gluz, O., Hansen, K., Hofmann, D., Kates, R., Mangold, M., Mathissen, M., Raeth, P., Renner, I., Reiser, I., Schumacher, J., Staedele, M., Walter-Kirst, R., Nitz, Ulrike, Gluz, Oleg, Clemens, Michael, Malter, Wolfram, Reimer, Toralf, Nuding, Benno, Aktas, Bahriye, Stefek, Andrea, Pollmanns, Anke, Lorenz-Salehi, Fatemeh, Uleer, Christoph, Krabisch, Petra, Kuemmel, Sherko, Liedtke, Cornelia, Shak, Steven, Wuerstlein, Rachel, Christgen, Matthias, Kates, Ronald E., Kreipe, Hans H., Harbeck, Nadia, Ackermann, S., Aktas, B., Augustin, D., Baake, G., Baumann, K., Berger, R., Bettscheider, J., Bischoff, J., Clemens, M., Deryal, M., Dubbers, H., Duchting, D., Dunnebacke, J., Fett, W., Fietz, T., Fischer, H., Forner, M., Forstbauer, H., Freese, K., Geberth, M., Glados, M., Gnauert, K., Goette, O., Gohring, U., Goppinger, A., Grafe, A., Hackenberg, R., Hackmann, J., Hellriegel, M., Heyl, V., Hoestermann, C., Hoffmann, G., Hofmann, M., Hucke, J., Jackisch, C., Jungberg, P., Just, M., Kahl, C., Klare, P., Kogel, M., Kohls, A., Amrawy, B. Konigs-El, Konnecke, P., Krabisch, P., Kraudelt, S., Kremers, S., Kummel, S., Kurbacher, C., Kusche, J., Liedtke, B., Liedtke, C., Link, H., Lorenz, R., Salehi, F. Lorenz, Lubbe, K., Malter, W., Melekian, B., Mobus, V., Montenarh, M., Mueller, V., Mundhenke, C., Niederle, N., Nitz, U., Noesselt, T., Oberhoff, C., Paas, L., Paepke, S., Pollmanns, A., Reichert, D., Reimer, T., Romann, D., Ruhland, T., Runde, V., Salem, M., Schlosser, A., Schneider, A., Schrader, I., Schulz, H., Schumacher, C., Schwickerath, J., Soling, U., Stauder, H., Stefek, A., Steinmetz, T., Stickeler, E., Terhaag, J., Thomssen, C., Tome, O., Uleer, C., Warm, M., Wachsmann, G., Wacker, J., Wiebringhaus, H., Wiest, W., Wolfgarten, M., Christgen, H., Kreipe, H., Buehne, C., Gluz, O., Hansen, K., Hofmann, D., Kates, R., Mangold, M., Mathissen, M., Raeth, P., Renner, I., Reiser, I., Schumacher, J., Staedele, M., and Walter-Kirst, R.

Abstract

PURPOSE The West German Study Group PlanB trial evaluated an anthracycline-free chemotherapy standard (six cycles of docetaxel and cyclophosphamide [TC]) in the routine treatment of human epidermal growth factor receptor 2-negative early breast cancer (EBC). PATIENTS AND METHODS Patients with pT1 to pT4c, all pN+, and pN0/high-risk EBC were eligible. High-risk pN0 was defined by one or more of the following: pT greater than 2, grade 2 to 3, high urokinase-type plasminogen activator/plasminogen activator inhibitor-1, hormone receptor (HR) negativity, and less than 35 years of age. After an early amendment, all HR-positive tumors underwent recurrence score (RS) testing, with chemotherapy omission recommended in RS less than or equal to 11 pN0 to pN1 disease. Patients were randomly assigned to four cycles of epirubicin (E)(90)/cyclophoshamide (C)(600) followed by four cycles of docetaxel (T)(100) or six cycles of T75C600 (administered once every 3 weeks). The primary end point was disease-free survival (DFS); secondary end points were overall survival (OS) and safety. The protocol specified P = .05 for a noninferiority margin of 4.4% for all patients combined. RESULT Of the 3,198 registered patients, 348 (RS <= 11) omitted chemotherapy, and 401 were not randomly assigned. The intention-to-treat population included 2,449 patients (1,227 EC-T v 1,222 TC: postmenopausal, 62.2% v60.8%; pNO, 58.2% v59.5%; pT1, 57.6% v52.3%; HR positive, 81.4% v82.2%; RS greater than 25 [in H.R-positive patients], 26.2% v 27.5%). Within the safety population (1,167 v 1,178 patients), 87.5% v 93.0% completed therapy. After a 60-month median follow-up, 5-year outcomes were similar in the EC-T and TC arms (DFS, 89.6% [95% CI, 87.9% to 91.5%] v89.9% [95% CI, 88.1% to 91.8%]; OS, 94.5% [95% CI, 93.1% to 95.9%] v94.7% [95% CI, 93.3% to 96.1%]). The DFS difference was within the noninferiority margin of the original trial design. Five treatment-related deaths were reported for TC (one for EC-T), de

Published
2019

37. Synthesis and Reactions of New Oxorhenium(V) Complexes with Re-Halogen Bonds. X-Ray Crystal Structure of 3-(Benzyl)azapentane-1.5-dithiolato)iodo-Oxorhenium(V)

Author

Fietz, T., Leibnitz, P., Spies, H., and Johannsen, B.

Abstract

Treatment of [ReO(SN(R)S)(SMe)] (HSN(R)SH=HS-CH2 CH2-N(R)- CH2 CH2-SH, R=n-propyl 4a, benzyl 4b) with an excess of CH3I at room temperature gave the-SCH3 displaced products [ReO(SN(R)S)I] 5a,b in about 80% yield. [(3-(Benzyl)azapentane-1,5-dithiolato)iodo]oxorheniumV 5b was characterized by single-crystal structure analysis revealing a distorted trigonal bipyramidal geometry with the oxygen and the sulfur atoms forming the equatorial plane. Compounds 5 allow clean transformation to new SNS/thiolato mixed ligand complexes as shown herein by a sample reaction with 1-beta-D-thiogalactose to give 6a.

Published
1999

42. Differences in Foxp3+ regulatory T cells in patients with intestinal graft-versus-host (GvH) disease, inflammatory bowel disease and infectious diseases

Author

Loddenkemper, C, primary, Rieger, K, additional, Fietz, T, additional, Berg, E, additional, Terpe, H, additional, Wolff, D, additional, Miehlke, S, additional, Bornhäuser, M, additional, Schneider, T, additional, Maul, J, additional, Zeitz, M, additional, Stein, H, additional, Thiel, E, additional, Uharek, L, additional, and Duchmann, R, additional

Published
2005
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results